M
Martine Extermann
Researcher at University of South Florida
Publications - 188
Citations - 14482
Martine Extermann is an academic researcher from University of South Florida. The author has contributed to research in topics: Cancer & Geriatric oncology. The author has an hindex of 52, co-authored 162 publications receiving 12660 citations. Previous affiliations of Martine Extermann include Moffitt Cancer Center.
Papers
More filters
Journal ArticleDOI
International Society of Geriatric Oncology Consensus on Geriatric Assessment in Older Patients With Cancer
Hans Wildiers,Pieter Heeren,Martine Puts,Eva Topinkova,Maryska L.G. Janssen-Heijnen,Martine Extermann,Claire Falandry,Andrew S. Artz,Etienne Brain,Giuseppe Colloca,Johan Flamaing,Theodora Karnakis,Cindy Kenis,Riccardo A. Audisio,Supriya G. Mohile,Lazzaro Repetto,Barbara L. van Leeuwen,Koen Milisen,Arti Hurria +18 more
TL;DR: There is mounting data regarding the utility of GA in oncology practice; however, additional research is needed to continue to strengthen the evidence base.
Journal ArticleDOI
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG).
Martine Extermann,Matti Aapro,Roberto Bernabei,Harvey J. Cohen,Jean Pierre Droz,Stuart M. Lichtman,Vincent Mor,Silvio Monfardini,Lazzaro Repetto,Liv Wergeland Sørbye,Eva Topinkova +10 more
TL;DR: A CGA, with or without screening, and with follow-up, should be used in older cancer patients, in order to detect unaddressed problems, improve their functional status, and possibly their survival.
Journal ArticleDOI
Comorbidity and functional status are independent in older cancer patients.
TL;DR: Both the Charlson and CIRS-G scales are reliable tools for use in trials of older cancer patients and can be tested in further studies as predictors of outcomes such as toxicity of treatment, changes in functional status, or survival.
Journal ArticleDOI
Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score
Martine Extermann,I. Boler,Richard R. Reich,Richard R. Reich,Gary H. Lyman,Richard Brown,J. Defelice,Richard M. Levine,Eric T. Lubiner,Pablo Reyes,Frederic J. Schreiber,Lodovico Balducci +11 more
TL;DR: Tools are lacking to assess the individual risk of severe toxicity from chemotherapy, and such tools would be especially useful for older patients, who vary considerably in terms of health status and functional reserve.
Journal ArticleDOI
Management of Cancer in the Older Person: A Practical Approach
TL;DR: All persons aged 70 and older, treated with cytotoxic chemotherapy of dose intensity comparable to CHOP, receive prophylactic growth factor treatment, and that the hemoglobin of these patients be maintained >/=12 gm/dl.